FAM70B As a Novel Prognostic Marker for Cancer Progression and Cancer-Specific Death in Muscle-Invasive Bladder Cancer

Overview

Journal Korean J Urol

Specialty Urology

Date 2012 Oct 13

PMID 23060996

Citations 7

Authors

Ho-Won Kang

Hyung-Yoon Yoon

Yun-Sok Ha

Won Tae Kim

Yong-June Kim

Seok-Joong Yun

Sang-Cheol Lee

Wun-Jae Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: To validate whether FAM70B, which was found in our micro-array profiling as a prognostic marker for cancer survival, could accurately predict prognosis in patients with muscle-invasive bladder cancer (MIBC).

Materials And Methods: A total of 124 patients with MIBC were enrolled in this study. The FAM70B expression level was analyzed by real-time polymerase chain reaction by using RNA from tumor tissues. The prognostic effect of FAM70B was evaluated by Kaplan-Meier analysis and a multivariate Cox regression model.

Results: Kaplan-Meier estimates showed a significant difference in progression-free survival (log-rank test, p=0.011) and cancer-specific survival (log-rank test, p=0.017) according to FAM70B gene expression level. By multivariate Cox regression analysis, high FAM70B expression was predictive of cancer progression (hazard ratio [HR], 2.115, p=0.013) and cancer-specific death (HR, 1.925; p=0.033). In the subgroup analysis, high expression of FAM70B was associated with poor cancer-specific survival, progression-free survival, and overall survival in the patients who underwent cystectomy (log-rank test, p=0.013, p=0.036, p=0.005, respectively). In the chemotherapy group, FAM70B expression was associated with cancer-specific survival and progression-free survival (log-rank test, p=0.013, p=0.042, respectively). Moreover, high FAM70B expression was associated with shorter cancer-specific survival in localized or locally advanced tumor stages (log-rank test, p=0.016).

Conclusions: We confirmed the significance of FAM70B as a prognostic marker in a validation cohort. Therefore, we propose that the FAM70B gene could be used to more precisely predict cancer progression and cancer-specific death in patients with MIBC.

Citing Articles

lncRNA and mRNA sequencing of the left testis in experimental varicocele rats treated with polysaccharide.

Zhang L, Zhao X, Wang W Exp Ther Med. 2021; 22(4):1136.

PMID: 34466146 PMC: 8383328. DOI: 10.3892/etm.2021.10570.

Systemic Mesenchymal Stem Cell Treatment Mitigates Structural and Functional Retinal Ganglion Cell Degeneration in a Mouse Model of Multiple Sclerosis.

Gramlich O, Brown A, Godwin C, Chimenti M, Boland L, Ankrum J Transl Vis Sci Technol. 2020; 9(8):16.

PMID: 32855863 PMC: 7422913. DOI: 10.1167/tvst.9.8.16.

Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer.

Kang H, Seo S, Jeong P, Ha Y, Kim W, Kim Y Oncol Lett. 2017; 14(2):2468-2474.

PMID: 28781684 PMC: 5530216. DOI: 10.3892/ol.2017.6408.

Centromere protein U is a potential target for gene therapy of human bladder cancer.

Wang S, Liu B, Zhang J, Sun W, Dai C, Sun W Oncol Rep. 2017; 38(2):735-744.

PMID: 28677729 PMC: 5562008. DOI: 10.3892/or.2017.5769.

A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.

Sun L, Lu J, Niu Z, Ding K, Bi D, Liu S PLoS One. 2015; 10(12):e0144484.

PMID: 26658059 PMC: 4675549. DOI: 10.1371/journal.pone.0144484.

References

Eschrich S, Yang I, Bloom G, Kwong K, Boulware D, Cantor A . Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005; 23(15):3526-35. DOI: 10.1200/JCO.2005.00.695. View

Dyrskjot L, Zieger K, Real F, Malats N, Carrato A, Hurst C . Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res. 2007; 13(12):3545-51. DOI: 10.1158/1078-0432.CCR-06-2940. View

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh J . The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol. 2006; 24(2):152-60. DOI: 10.1016/j.urolonc.2005.11.004. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

Kim Y, Kim W . Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol. 2008; 16(1):17-22. DOI: 10.1111/j.1442-2042.2008.02143.x. View

Kaufman D, Shipley W, Feldman A . Bladder cancer. Lancet. 2009; 374(9685):239-49. DOI: 10.1016/S0140-6736(09)60491-8. View

Gerhard D, Wagner L, Feingold E, Shenmen C, Grouse L, Schuler G . The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004; 14(10B):2121-7. PMC: 528928. DOI: 10.1101/gr.2596504. View

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

10.

Kim S, Kim E, Leem S, Ha Y, Kim Y, Kim W . Identification of S100A8-correlated genes for prediction of disease progression in non-muscle invasive bladder cancer. BMC Cancer. 2010; 10:21. PMC: 2828413. DOI: 10.1186/1471-2407-10-21. View

11.

Chen H, Yu S, Chen C, Chang G, Chen C, Yuan A . A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007; 356(1):11-20. DOI: 10.1056/NEJMoa060096. View

12.

Catto J, Azzouzi A, Rehman I, Feeley K, Cross S, Amira N . Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005; 23(13):2903-10. DOI: 10.1200/JCO.2005.03.163. View

13.

Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T . Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005; 11(7):2625-36. DOI: 10.1158/1078-0432.CCR-04-1988. View

14.

Ha Y, Kim M, Yoon H, Kang H, Kim Y, Yun S . mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer. Korean J Urol. 2010; 51(1):15-20. PMC: 2855462. DOI: 10.4111/kju.2010.51.1.15. View

15.

Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen J, Marcussen N, Hamilton-Dutoit S . Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet. 2002; 33(1):90-6. DOI: 10.1038/ng1061. View

16.

Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen J, Moller K . Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 2004; 64(11):4040-8. DOI: 10.1158/0008-5472.CAN-03-3620. View

17.

Jung K, Park S, Kong H, Won Y, Lee J, Seo H . Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 2012; 44(1):11-24. PMC: 3322196. DOI: 10.4143/crt.2012.44.1.11. View

18.

Lossos I, Czerwinski D, Alizadeh A, Wechser M, Tibshirani R, Botstein D . Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004; 350(18):1828-37. DOI: 10.1056/NEJMoa032520. View

19.

Weinstein J, Scherf U, Lee J, Nishizuka S, Gwadry F, Bussey A . The bioinformatics of microarray gene expression profiling. Cytometry. 2002; 47(1):46-9. DOI: 10.1002/cyto.10041. View

20.

Kim W, Kim S, Jeong P, Yun S, Cho I, Kim I . A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med. 2011; 17(5-6):478-85. PMC: 3105150. DOI: 10.2119/molmed.2010.00274. View